KFAED signs $2.5mln grant deal with WHO for Yemen health project
KUWAIT - Kuwait Fund for Arab Economic Development (KFAED) signed Tuesday a deal with World Health Organization (WHO), offering USD 2.5 million to support enhanced access to renewable energy sources for healthcare facilities in Yemen.
The project is meant to improve the quality of basic health services for the population, cut the reliance of health facilities on unreliable energy sources, and reduce carbon emissions by providing six hospitals with continuous and reliable renewable energy sources, KFAED said in a press release.
These health facilities will annually serve about 935,000 people directly and about 1.6 million additional indirectly, it added.
The project involves design, supply, installation and maintenance services for solar energy systems, energy storage batteries and ancillary components to supply health facilities with solar energy to operate priority departments, it explained.
The KFAED pointed out that the project implementation period is expected to take about two years.
KFAED Acting Director General Waleed Al-Bahar and WHO Representative to the State of Kuwait Dr. Assad Hafeez signed the grant agreement.
This grant is the tenth contribution of its kind between the two institutions in the field of humanitarian support, as the fund has previously provided about USD 25 million to the WHO since 1994 to finance nine projects.
All KUNA right are reserved © 2022. Provided by SyndiGate Media Inc. (Syndigate.info).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
8 hours ago
- Zawya
Angola takes a decisive step towards ensuring safer, more effective, and more accessible medicines and health technologies
Between June 3 and 5, the Angola Medicines and Health Technologies Regulatory Agency (ARMED), with technical support from World Health Organization (WHO) and funding from the European Union (EU), held a strategic meeting to monitor progress in implementing the recommendations made as part of the assessment of its regulatory maturity. The session was attended by 25 ARMED professionals and resulted in the drafting of the Institutional Development Plan (IDP), the aim of which is to strengthen the national regulatory system, bringing it into line with international standards, in a context in which the pharmaceutical sector is becoming increasingly attractive for investment. According to WHO Representative in Angola, Dr. Indrajit Hazarika, supervision is an essential pillar of the pharmaceutical sector, encompassing a complex network of production, distribution, and marketing medicines. Dr. Hazarika stressed that 'medicines and medical products are fundamental for access to health care, and it is essential to guarantee their quality so that the goal of health for all can be achieved'. This meeting is part of WHO's ongoing support to the Angolan government in strengthening the regulatory system. WHO experts from the Geneva headquarters and the Africa regional and national offices analyzed the Angolan regulatory system based on WHO Quality Management System principles and the international benchmarking tool - the Global Benchmarking Tool (GBT). During the meeting, the progress made in implementing the technical recommendations was assessed, and a review was also made of the actions taken following the 2022 and February 2024 self-assessment exercises. The Institutional Development Plan (IDP) was updated in this context, a strategic document that will guide ARMED until 2027. The aim is to reach Maturity Level 3, internationally recognized as the benchmark for a functional regulatory system, capable of guaranteeing the availability of safe, effective, and quality medicines on the national market. Despite the progress already made, the pace of implementation needs to be accelerated. Holding regular meetings to follow up on the IDP is key to monitoring progress, identifying obstacles, adjusting strategies, and ensuring continued alignment with international standards. In addition, these meetings also strengthen institutional commitment, promote transparency, and facilitate coordination between technical and financial partners. ARMED's Director General, Dr. Pombal Mayembe, stressed the importance of the initiative. 'At the World Health Assembly, there was extensive discussion about the local production of medicines. Angola cannot be left out of this movement. We want to reach level 3 of maturity by 2027. Is that possible? Yes, with the support of WHO, EU, and other partners, we are firmly committed to achieving this goal.' For his part, Pierre Destexhe, representing the European Union, highlighted ARMED's role in controlling the quality of the national medicines market, as well as its contribution to ensuring that access to safe, quality medicines becomes an ever greater reality in Angola, within the scope of Universal Health Coverage. The meeting, which made it possible to assess progress and draw up ARMED's IDP, represents a decisive step towards consolidating a robust regulatory system in Angola, reaffirming the government's commitment to guaranteeing the population's access to safe, quality medicines, while at the same time promoting local production based on international standards. Distributed by APO Group on behalf of World Health Organization (WHO) - Angola.
Arabian Post
15 hours ago
- Arabian Post
MediLink Therapeutics Taps Major Banks for Hong Kong Float
MediLink Therapeutics Ltd. is preparing to launch an initial public offering in Hong Kong, having secured China International Capital Corp., JPMorgan Chase & Co. and Morgan Stanley as its lead advisers, according to people with knowledge of the matter. The move comes as the clinical-stage biotech firm seeks to capitalise on growing investor interest in advanced tumour-targeting therapies and consolidate its platform of antibody‑drug conjugates. Founded in 2020 and headquartered in Suzhou with R&D operations in Shanghai and Boston, MediLink has developed a proprietary ADC technology known as TMALIN®. The platform facilitates precise delivery of cytotoxic agents to tumour cells, with the intention of widening therapeutic windows for solid tumour treatments. Its pipeline includes programs that have advanced to clinical stages in both China and the United States, supported by a Series B financing round of approximately USD 70 million in 2022. MediLink's strategic engagement of three underwriters reflects heightened confidence in anchor investors and broader syndication. China International Capital Corp. brings deep roots in Chinese capital markets and extensive IPO experience in the biotech sector. JPMorgan and Morgan Stanley add global banking heft and access to international investors. ADVERTISEMENT CICC itself is emerging as a top-tier sponsor for Hong Kong listings. It led or co-led 19 IPOs for Chinese corporates last year, raising USD 3.84 billion, positioning it as a dominant force amid market revival. The engagement of internationally renowned banks alongside CICC is likely aimed at boosting MediLink's valuation and widening investor interest both locally and abroad. While IPO details remain confidential, analysts suggest MediLink could seek a valuation in the mid‑to‑high hundreds of millions of dollars. That would reflect both the advanced stage of its pipeline and prevailing market multiples for ADC developers. Comparable biotech flotations in Hong Kong and the U.S. have reflected growing appetite for oncology-focused platforms. Alongside listing ambitions, MediLink continues to advance its clinical and licensing goals. In March it unveiled preclinical data at the American Association for Cancer Research annual meeting; earlier in the year it received FDA clearance for its IND application for YL217, its lead candidate. YL201, another programme, received Breakthrough Therapy Designation in January for treatment of recurrent/metastatic nasopharyngeal carcinoma. The company has also pursued strategic licensing agreements with global pharmaceutical firms to expand development and commercialisation capabilities. A licensing deal under discussion ahead of the IPO is believed aimed at enhancing distribution reach while reinforcing MediLink's balance sheet. The IPO effort is part of a broader resurgence in biotech listings in Hong Kong, where authorities have eased regulations to attract innovation-driven offerings. CICC and other banks have ramped up support for ADC and gene therapy companies, signalling a turning point after a lull in listings. ADVERTISEMENT MediLink's choice of banks aligns with a wider trend: CICC has co-sponsored blockbuster floats including the forthcoming mega‑IPO of CATL, while banks like Goldman Sachs and Morgan Stanley have also participated. In this context, MediLink is positioning itself to tap both deep domestic networks and international capital. Stakeholder sentiment appears optimistic. MediLink's management team, comprised of co‑founders Tony Xue and Jiaqiang Cai alongside C‑suite leaders experienced in drug development and financial strategy, has overseen steady progress in its ADC pipeline and established global partnerships. Jason Li's appointment as CFO in 2023 reportedly strengthened the company's capital market readiness. Market observers highlight challenges ahead. ADC development remains capital-intensive, clinical risks high, and competition fierce among domestic and international peers. Success will hinge on late‑stage data and licensing traction. At the same time, geopolitical tensions and volatility in Hong Kong equity markets may affect investor sentiment. MediLink must also navigate post‑IPO obligations, including regulatory reporting and corporate governance under Hong Kong's Main Board requirements. Mitigating execution risk will be critical, underscoring the role of its chosen bankers in underwriting diligence and market support. Analysts describe the listing as a pivotal moment: it offers the backing to fund Phase II/III efforts while elevating MediLink's corporate profile. For banks, it reinforces Hong Kong's appeal as a biotech capital market when compared with established centres like Nasdaq. With its IPO process underway, MediLink now awaits market timing and regulatory clearances before formally filing a prospectus. The company is expected to continue advancing clinical data, strengthening licensing ties, and preparing investor materials aligned with regulatory requirements.
Zawya
a day ago
- Zawya
The World Health Organization (WHO) Donates Mobile Water Testing Kits to Boost Angola's Water Safety Monitoring
The World Health Organization (WHO) today donated three mobile water quality testing kits to the Ministry of Health, through the Instituto Nacional de Investigação em Saúde (INIS), to strengthen Angola's capacity to monitor and respond to waterborne disease risks—especially during health emergencies such as the ongoing cholera outbreak. These mobile kits allow for on-the-spot analysis of water sources, enabling health teams to detect issues such as pH levels, chlorine concentration, turbidity, and other key indicators of water safety—without the delays caused by transporting samples to laboratories. 'In provinces like Lunda Norte, we've faced serious challenges collecting and transporting water samples from remote communities,' said Alex Freeman, a WASH and Health logistics specialist deployed to Angola with the support of the WHO Nairobi AFRO Emergency Hub 'Now, with these mobile kits, we can conduct accurate tests immediately at the point of collection, enabling faster decision-making and a more agile public health response.' As part of the rollout, nine INIS staff members were trained on the use of the mobile kits, with additional training planned for personnel from other sectors in the coming weeks. The testing kits are also a practical tool for routine monitoring in hospital settings, helping ensure safe water for patients and health workers. As part of WHO's mandate to support water quality surveillance, the kits represent an important operational boost for both preventive health efforts and outbreak response. 'This is a great example of collaboration and targeted support,' said Simão Nhassengo, a WASH specialist deployed to Angola with the support of the government of the Netherlands. 'These kits will play an important role in monitoring water safety across Angola and ultimately help prevent the spread of waterborne diseases like cholera.' The initiative was made possible thanks to the generous contributions of the European Union through European Civil Protection and Humanitarian Aid Operations (ECHO), and the Embassy of the Netherlands, whose support has also enabled technical deployments to strengthen water, sanitation, and hygiene (WASH) capacity across the country. Distributed by APO Group on behalf of World Health Organization (WHO) - Angola.
